Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China

An, Ping; Ji, Mengyao; Ren, Haixia; Su, Juan; Ding, Nik S.; Kang, Jian; Yin, Anning; Zhou, Qian; Shen, Longjiao; Zhao, Liang; Jiang, Xiaoda; Xiao, Yong; Tan, Wei; Lv, Xiaoguang; Li, Jiao; Liu, Shuzhong; Zhou, Jing; Chen, Hongbin; Xu, Yanyi; Li, Jun; Chen, Miao; Cao, Jun; Zhou, Zhongyin; Shen, Lianfeng; Sheng, T. T.; Yu, Honggang; Dong, Weiguo; Ding, Yijuan

doi:10.1016/s2468-1253(20)30121-7

Cited by 85 publications

(98 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…If this was the case our data would indicate that IMID patients treated with cytokine inhibitors also have a reduced susceptibility to infections with endemic coronaviruses. Furthermore, virtual absence and/or mild clinical course of clinical COVID-19 infection in IMID patients 21 – 24 argues for reduced susceptibility of these patients to SARS-CoV-2 and supports the concept of a protective or at least mitigating effect of treatment with cytokine-blocking drugs.…”

Section: Discussionmentioning

confidence: 82%

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

et al. 2020

View full text Add to dashboard Cite

Immune-mediated inflammatory diseases (IMIDs) of the joints, gut and skin are treated with inhibitors of inflammatory cytokines. These cytokines are involved in the pathogenesis of coronavirus disease 2019 (COVID-19). Investigating anti-SARS-CoV-2 antibody responses in IMIDs we observe a reduced incidence of SARS-CoV-2 seroconversion in IMID patients treated with cytokine inhibitors compared to patients receiving no such inhibitors and two healthy control populations, despite similar social exposure. Hence, cytokine inhibitors seem to at least partially protect from SARS-CoV-2 infection.

show abstract

Section: Discussionmentioning

confidence: 82%

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In Wuhan, China, a popular social media app has allowed instructional alerts to be disseminated to all patients with IBD. 9 Third, there is a need to facilitate patient access to IBD-related information from credible sources, particularly since the internet can amplify misinformation. 9 With resources such as the IBD helpline stretched to the maximum, there is a need to develop innovative solutions using artificial intelligence through collaboration with digital technology partners.…”

Section: Discussionmentioning

confidence: 99%

COVID-19-related health anxieties and impact of specific interventions in patients with inflammatory bowel disease in the UK

Mir

Cheesbrough

Troth

et al. 2020

Frontline Gastroenterol

View full text Add to dashboard Cite

ObjectiveHealth-related concerns brought on by the COVID-19 pandemic and the impact of specific local and national interventions have not been explored in patients with inflammatory bowel disease (IBD) in the UK. We evaluated perspectives of patients with IBD on the pandemic and effectiveness of information dissemination in addressing concerns.MethodsWe prospectively conducted a survey among patients with IBD during the COVID-19 pandemic to assess concerns, information-seeking behaviours, risk perception, compliance and effect of specific interventions.ResultsA total of 228 patients were interviewed of whom 89% reported being concerned about the impact of COVID-19 on their health. Access to at least one IBD-specific clinical interaction during the pandemic (COVID-19 information letter from IBD team, interaction with IBD team or general practitioner, Crohn and Colitis UK website visit) was significantly associated with alleviating concerns (OR 2.66; 95% CI 1.35 to 5.24; p=0.005). Seeking health information solely through unofficial channels (search engines or social media) was less likely to ease concerns (OR 0.15; 95% CI 0.03 to 0.61; p=0.008). A quarter of patients disagreed with their assigned risk groups, with majority perceiving higher-risk profiles. This discordance was greatest in patients within the moderate-risk group and constituted immunosuppression use. Nearly 40% of patients had ongoing concerns with regard to their medications of whom a third felt their concerns were not addressed.ConclusionIBD-specific clinical interactions are associated with alleviation of COVID-19 health concerns. These findings have wider implications and emphasise importance of innovative solutions that facilitate effective communication with patients without overburdening current services.

show abstract

“…Preliminary studies did not report any COVID-19 cases in patients with IBD ( 1 , 2 ). However, subsequent studies including the Surveillance Epidemiology of Coronavirus Under Research Exclusion-IBD database, which includes global data of patients with IBD and COVID-19 ( 3 ), several cohort studies ( 4 – 9 ), and case reports ( 10 – 12 ), have reported 1,258 patients with IBD affected by COVID-19.…”

Section: Epidemiology Of Covid-19 In Ibdmentioning

confidence: 96%

Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease

2020

View full text Add to dashboard Cite

INTRODUCTION: It has been hypothesized that people suffering from inflammatory bowel disease (IBD) have an increased risk of coronavirus disease (COVID-19). However, it is not known whether immunosuppressive therapies exacerbate the COVID-19 outcome. METHODS: We reviewed data on the prevalence and clinical outcomes of COVID-19 in patients with IBD. RESULTS: COVID-19 prevalence in patients with IBD was comparable with that in the general population. Therapies using antitumor necrosis factor-α agents have been associated with better clinical outcomes. DISCUSSION: Management and treatments provided by gastroenterologists were effective in reducing COVID-19 risk. Antitumor necrosis factor-α agents seem to mitigate the course of COVID-19.

show abstract

Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China

Cited by 85 publications

References 1 publication

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

COVID-19-related health anxieties and impact of specific interventions in patients with inflammatory bowel disease in the UK

Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease

Contact Info

Product

Resources

About